ObjectivesTo describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity. MethodsA retrospective study was carried out of all women prescribed nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland (October 2000 to February 2003. Toxicities experienced were graded according to the Division of AIDS toxicity guidelines for adults. Statistical analysis was performed to determine whether there were differences between those that did and those that did not experience significant hepatotoxicity. ResultsA total of 123 women initiated nevirapine as part of combination antiretroviral therapy in the study period. Eight women developed significant hepatotoxicity, including two women who died from fulminant hepatitis. Women who experienced more severe hepatotoxicity had higher pretreatment CD4 counts (P 5 0.01). ConclusionsIn this cohort, women who experienced more severe hepatotoxicity had higher pretreatment CD4 counts, lending additional weight to the need for caution in using nevirapine as part of combination antiretroviral therapy in women not requiring antiretroviral therapy for their own health.

AbstractsWithin the obese group, there was no significant difference between ETP levels before and after fixed LMWH dose. However, ETP levels were significantly lower post weight-adjusted dose (75 iu/kg tinzaparin) compared with post fixed dose. There was a significant effect of LMWH on TFPI levels, (p < 0.0001). ETP correlated positively with total body weight at fixed dose (r = 0.578) (p < 0.05). Conclusion Morbidly obese pregnant women have increased thrombin generation and reduced natural anticoagulant in third trimester. The prothrombotic state in pregnant morbidly obese women was substantially attenuated by weight adjusted but not at fixed LMWH doses.The Use of QUanTiTaTive feTal fibronecTin To PredicT obsTeTric oUTcome: a comParison of a new and esTablished QUanTiTaTive bedside analyser in asymPTomaTic high-risk women

No abstract